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HIV AND PMTCT IN LESOTHO
Despite its small size, Lesotho has the second 
highest HIV prevalence globally. HIV prevalence 
was 23.6 percent in 2018, approximately the same 
rate which has been observed since 2005.1 Women 
disproportionately share this burden in Lesotho; out 
of the 330,000 adults living with HIV, 58 percent 
were women. Additionally, new HIV infections among 
young women aged 15–24 years were more than 
double those among young men2 and account for 
approximately one quarter of all new adult HIV 
infections every year.3
Optimizing Maternal, Newborn, and Child Health 
Outcomes Through Use of Multidisciplinary 







	● The total average unit cost for each of the five 
services—antenatal care (ANC), family planning 
(FP), prevention of mother-to-child-transmission 
(PMTCT), postnatal care (PNC), and pediatric 
antiretroviral therapy (ART)—was higher in 
the intervention arm when compared to the 
control arm of the study. The unit cost for ANC 
services was $205 and $277 in the control 
versus intervention arms, respectively. The cost 
of FP was $81 in the control arm and $87 in 
the intervention arm. The unit cost for PMTCT 
services was $296 in the control arm versus 
$311 in the intervention arm. The cost for PNC 
services was $84 in the control arm and $97 
in the intervention arm. The cost of pediatric 
ART was $321 and $347 for the control and 
intervention arms, respectively.
	● The cost of the IMPROVE intervention is 
substantially higher for ANC services (35%) 
compared to current treatment protocol in 
Lesotho. However, the cost for subsequent 
services were only slightly higher in the 
intervention arm compared to the control arm—
FP (8%), PMTCT (5%), PNC (15%), and pediatric 
ART (8%).
	● The cost of the IMPROVE intervention, especially 
the integrated approach for FP, PMTCT, and 
pediatric ART, is not prohibitive, and has the 
potential to improve coordination of care at 
relatively low cost to existing services. 
	● Scaling up the intervention would not require 
a significant amount of financial support or 
significant human resources.
	● As this intervention builds primarily on an already 
existing healthcare system and infrastructure, 
there is potential to expand it beyond PMTCT care 
models.
	● The results from this analysis add to the current 
body of evidence on health costing being collated 
by the Global Health Cost Consortiuma and can 
also be utilized for additional analysis (HIV, FP, 
PMTCT, etc.) and impact modeling applications.
aAccessed via GHCosting.org 
Attrition in HIV care and treatment for the general 
population is around 20 percent; attrition for HIV-
positive pregnant women in prevention of mother-
to-child transmission (PMTCT) programs is similar.4 
The Lesotho government has attempted to address 
issues in retention using various interventions; 
however, the coordination of these at both the facility 
and community level is somewhat convoluted. For 
example, there is a lack of standardized job aids 
or tools to assist in managing patients among 
cadres at the facility level, to help ensure consistent 
messaging and care coordination. Furthermore, 
the role that village health workers (VHWs) play in 
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have historically dropped out. Additionally, it is 
also expected that there will be broader benefits 
of the intervention among both HIV-positive and 
HIV-negative women and their infants, as their care 
becomes more integrated and actively managed.
From a financial perspective, the cost of 
implementation is expected to be low, as it leverages 
the existing health care system and does not 
introduce any particularly costly components. This 
brief describes the approach and key quantitative 
findings of the costing component of the IMPROVE 
intervention from the service provider perspective.
RESEARCH QUESTIONS
The aim of the costing component of this study 
is to determine the cost of the arms—control 
(current standard treatment protocol) relative to 
the intervention (IMPROVE)—and to identify key cost 
drivers for each. Specifically, the aim is to estimate:
1. The cost per person per year (i.e., unit cost) of 
each of the five key IMPROVE services: general 
MNCH, which includes both ANC and PNC; FP; 
PMTCT; and pediatric ART services.
2. The major cost components/drivers of the five 
key IMPROVE services. 
Understanding these costs will provide evidence 
for those considering the scale up or expansion of 
the IMPROVE intervention. Evidence from these 
costing analyses can also help inform policy 
recommendations to improve existing PMTCT/MNCH 
services. 
METHODS
IMPROVE used a cluster randomized study design 
with 12 facilities randomized to receive either 
routine MNCH/PMTCT care based on current 
treatment protocol plus the IMPROVE intervention, 
or a control group, which offered routine care 
based on current treatment protocol only. These 
facilities were all based in Maseru district, which 
includes both rural and urban settings, and reflects 
a range of service delivery modes. A cohort of 1,004 
women (614 HIV-negative and 390 HIV-positive) 
supporting new mothers in maternal, newborn, and 
child health (MNCH)/PMTCT care is not clearly linked 
to facility-based services. While support groups exist 
for mothers, social and cultural stigma remains and 
affects uptake of these services. 
In response to these challenges, the Elizabeth 
Glaser Pediatric AIDS Foundation (EGPAF) designed 
the multidisciplinary “Integrated Management Team 
to Improve Maternal-Child Outcomes (IMPROVE)” 
intervention to improve patient-centered care 
and to boost uptake of family planning (FP) and 
MNCH services (specifically, antenatal care 
[ANC] and postnatal care [PNC]) as well as to 
improve adherence and retention for patients on 
antiretroviral therapy (ART). This study builds on 
the USAID-funded PMTCT service delivery program 
already being implemented by EGPAF in Lesotho. 
Rather than designing a suite of entirely new 
services and delivery platforms, the intervention 
focused on improving existing services and 
strengthening the connection between facility and 
community-based care through:
1. The creation of multidisciplinary integrated 
management teams, combining facility-based 
MNCH providers, VHWs, and representatives 
from community-based organizations 
(mothers2mothers [m2m] and Lesotho Network 
of AIDS Service Organizations [LENASO]), who 
meet regularly to improve coordination of care 
and follow-up for patients lost to follow-up.
2. Enhanced Positive Health, Dignity, and 
Prevention (PHDP)-focused training and job aids 
to improve care and counseling provided by 
IMPROVE team members.
3. Increased community-based support via an 
additional home visit one to two weeks following 
the first ANC visit to reduce loss to follow-up 
among new mothers.
Due to various factors, pregnant women have 
struggled to remain on ART during pregnancy and 
during the post-partum period. By strengthening 
team-based care at the facility-level and providing 
an additional home-based visit during the initial 
post-partum period, the IMPROVE intervention 
can help target these points in care where women 
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were enrolled in the study at their first ANC visit 
and followed until the last set of study participants 
recruited were at 12 months post-delivery. The effect 
of IMPROVE was evaluated via primary outcomes, 
including treatment retention, adherence, viral 
suppression, and HIV retesting (perinatally and at 12 
and 24 months postpartum), as well as via various 
secondary outcomes measuring uptake of MNCH 
services. 
The cost evaluation of facility-based delivery of 
IMPROVE services began in November 2018. 
Data collection instruments were designed in 
collaboration with EGPAF staff to collect data from 
multiple sources including facility, district, and 
national health staff and patient forms. After an 
initial pilot-testing period, adjustments were made 
to data collection forms to reflect availability of 
aggregate patient service delivery and cost data. 
These data were collected from interviews with staff 
at the facility, district, and national levels of the 
Ministry of Health and their implementing partners 
(including EGPAF) by a team of Maseru-based 
costing consultants. Data on service delivery—types 
of services offered at the site, number of patients or 
patient visits by service, and total number of patients 
or patient visits—were collected from summary 
registration forms and cross-referenced with MoH’s 
District Health Information Software (DHIS2). The 
cost data were categorized by the following cost 
components: 
1. Clinical staff costs: These are defined as the 
estimated time facility-based clinical providers 
reported spending with the average patient 
through specific stages (registration, triage, 
counseling and testing, consultation, adherence 
counseling, pharmacy, etc.) during a visit by 
type of service (ANC, FP, PMTCT, PNC, and 
pediatric ART). The costs are then calculated 
by multiplying the reported time spent by the 
average salary of providers by cadre, the average 
number of staff providing services at each 
stage of care by staff cadre, and the estimated 
number of visits per year for each type of 
service.
2. Laboratory costs: These include the cost of 
lab commodities (test kits, lab tests, etc.) and 
the estimated time, reported by lab staff, spent 
conducting lab tests (blood draw, running test, 
interpreting test) for each type of patient by 
service. It also includes the average cost of 
transporting samples from facilities to testing 
laboratories (based on national average sample 
transportation costs). As with clinical staff costs, 
lab staff costs are then calculated by multiplying 
the reported time spent running each type of 
test (HIV, dried-blood spot) by the average salary 
of staff and the estimated number of tests per 
patient per year for each type of service. Lab 
testing occurs at either one of three of the 12 
study facilities or at the National Reference 
Laboratory. Costs were collected from all three 
facilities, as well as from the National Reference 
Laboratory. As such, the time spent by lab staff 
and salary of staff cadres who performed lab 
services were averaged across these three 
sources and applied to each of the 12 facilities. 
3. Support staff costs: These are defined as time 
spent by facility-based staff who do not provide 
direct clinical services to patients but whose 
work supports these services at the facility (for 
example, night guard, cleaner, accountant/
bookkeeper). The costs are then calculated for 
each cadre by multiplying the reported time 
spent by the average salary of each support 
staff cadre based at that facility and the 
estimated proportion of time spent supporting 
each type of service reported by the same 
facility. Where the support staff were unable to 
provide an estimate of the time spent supporting 
each type of service, costs were estimated by 
multiplying the staff salary by the proportion of 
patients or patient visits by service area. The 
patient proportion by service area is calculated 
by dividing the number of patients or patient 
visits for each service area by the total number 
of patients or patient visits for each facility, 
respectively, depending on which of these two 
sets of data is available.
4. Integrated multidisciplinary management 
team costs: This is defined as the average 
amount of time each facility’s multidisciplinary 
team member spends in meetings to improve 
coordination of care and follow-up for patients 
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facility, respectively, depending on which of 
these two sets of data is available.
8. Equipment costs: These are the cost of 
medical equipment and furniture estimated by 
amortizing the cost of each piece of equipment 
used the year it was purchased, its lifespan/
replacement period, and whether or not it was 
used for each of the types of services. Like 
operating costs, these costs are apportioned to 
each of the service areas for each facility using 
the number of patients or patient visits divided 
by the total number of patients or patient visits 
for each facility, respectively, depending on 
which of the two sets of data is available.
All financial and cost data were collected in local 
currency (Maloti) and then converted to U.S. dollars 
(USD) using the average exchange rate over the 
study period (November 2017 to October 2019).b 
All 12 facilities offered ANC, HCT, PMTCT, PNC, and 
pediatric ART services. Only 5 of the 12 facilities 
offered FP services—two in the control arm and three 
in the intervention arm (including one hospital). 
Some of the costs pertaining to the intervention 
could not be separated from general program 
costs, specifically pre-implementation costs for the 
development of job aids, training at the site level 
for use of these aids, and start-up costs of the 
multidisciplinary team meetings, and thus were not 
available for analysis. The incremental cost of the 
additional home visit was also not available as it 
was performed for all patients (including non-study 
participants) and across all facilities (including non-
study facilities); as such it could not be allocated to 
either the control or intervention arm. 
To compare between control and intervention facility 
costs, data were averaged across the six facilities 
in each of the two arms. Since FP services were 
only offered in two control and three intervention 
facilities, FP service costs were averaged for these 
two groups of facilities for comparison. Lastly, the 
bInternational Monetary Fund, Representative Exchange rates  





lost to follow-up. This cost is calculated by the 
amount of reported time spent in meetings per 
month multiplied by the average salary of each 
team member and the number of meetings a 
year (12). These costs are apportioned to each 
of the five service areas for each facility using 
the number of patients or patient visits divided 
by the total number of patients or patient visits 
for each facility, respectively, depending on 
which of these two sets of data is available.
5. District health management team: This is 
the cost of the average reported time spent by 
the Maseru district health management staff 
supervising and supporting each facility program 
and the average time spent visiting/supervising 
each facility per month multiplied by the number 
of months in a year (12) and the average annual 
salary of each cadre of the district health 
management team. These district support teams 
also include MOH as well as implementing 
partner staff.
6. Drugs and commodities costs: This is 
calculated as the average quantity of each drug, 
medical commodity, and supply item used during 
a patient visit for each type of service reported 
by facility-based clinical providers multiplied 
by that cost per item of that drug, medical 
commodity, or supply. The cost of two key drugs 
and commodities—ARVs and contraceptive 
commoditiesa—were calculated using an average 
weighted cost based on the number of patients 
on each of the four major ARV regimens used 
by patients across the 12 sites5 and the five 
contraceptive methods reported in Lesotho’s 
most recent DHS survey,6 respectively.
7. Operating costs: This is defined as the cost 
of utilities (water, telephone, electricity, etc.), 
transportation (per diem, mobile and emergency 
vehicle maintenance, etc.), and maintenance 
costs (building and equipment maintenance). 
These costs are apportioned to each of the 
service areas for each facility using the number 
of patients or patient visits divided by the total 
number of patients or patient visits for each 
aNational Drug Service Organization-Central Store Price List 
and UNFPA/Lesotho price list.
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percentage cost difference of each service area 
was calculated by subtracting the total average unit 
cost of each service in the control arm from the 
total average unit cost of the corresponding service 
in the intervention arm, the result of which is then 
divided by the total average unit cost of that service 
in the control arm and multiplied by 100 to convert 
to percent. 
RESULTS
The average cost per person per year for each of 
the five service areas and the percentage difference 
(intervention cost relative to control cost) by study 
arm are shown in Table 1.
As anticipated, the estimated total average unit cost 
was highest for PMTCT and pediatric ART patients, 
in both arms. The total average unit cost for PMTCT 
patients was $296 in the control arm versus $311 
in the intervention arm, while the total average unit 
cost for pediatric patients was $321 and $347 for 
the control and intervention arms, respectively. The 
total average unit cost for ANC services are $205 
and $277 in the control versus intervention arms, 
respectively. However, it is important to note that 
when the $14.69 cost of counseling and testing 
(including the cost of HIV test kits) are excluded from 
ANC services, the cost falls to $190 and $263 in the 
control and intervention study arms, respectively. 
The total average unit cost for PNC services is 
approximately $84 in the control arm and $97 in the 
intervention arm. The total average cost per woman 
per year for FP services in the control arm was $81 
in the control arm and $87 in the intervention arm. 
The total average unit cost for each of the services 
provided in the intervention arm were relatively 
higher than the total average unit cost in the control 
arm. The results show that the percentage cost 
difference for FP, PMTCT, and pediatric ART were 
8 percent, 5 percent, and 8 percent, respectively. 
The intervention cost of PNC was 15 percent higher 
than the control cost, while ANC had the highest 
percentage cost difference at 35 percent. 
The cost per person by service area is further 
disaggregated into eight cost categories, which are 
displayed in Table 2.





Cost difference (intervention 
cost–control cost)
USD
Percentage difference of 
intervention cost relative  
to control cost
%
Antenatal care 205 277 72 35
Family planning 81 87 6 7
PMTCT 296 311 15 5
Postnatal care 84 97 13 15
Pediatric ART 321 347 26 8
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Table 2  Unit cost by service and by cost proportions—control and intervention arms
Service area/cost component Control InterventionCost (USD) Cost (%) Cost (USD) Cost (%)
Antenatal care
Clinical staff costs  46.01 22  49.19 18
Laboratory costs  108.19 53  112.39 41
Support staff costs  0.03 0  0.02 0
Multidisciplinary team costs  NA 0  54.78 20
District health staff costs  0.02 0  0.02 0
Drugs and commodities  8.07 4  14.63 5
Operating costs  13.39 7  25.67 9
Equipment costs  29.32 14  20.51 7
Family planning
Clinical staff costs  46.37 58  37.28 43
Laboratory costs  — 0 — 0
Support staff costs  0.03 0  0.01 0
Multidisciplinary team costs NA 0  22.58 26
District health staff costs — 0  0.02 0
Drugs and commodities 33.82 42  26.82 31
Operating costs 0.14 0  0.19 0
Equipment costs 0.26 0  0.28 0
PMTCT
Clinical staff costs 89.26 30  95.66 30.8
Laboratory costs 75.79 26  80.54 25.9
Support staff costs 0.03 0  0.01 0.0
Multidisciplinary team costs NA 0  5.28 2
District health staff costs 0.04 0  0.03 0
Drugs and commodities 117.07 39  115.84 37
Operating costs 5.33 2  8.24 2.7
Equipment costs 8.96 3  4.97 1.6
Postnatal care
Clinical staff costs 46.01 55  49.19 51
Laboratory costs — 0 — 0
Support staff costs 0.02 0 0.01 0
Multidisciplinary team costs NA 0 10.43 11
District health staff costs 0.02 0 0.01 0
Drugs and commodities 7.64 9 10.58 11
Operating costs 13.65 16 12.22 13
Equipment costs 16.69 20 14.54 15
Pediatric ART
Clinical staff costs 124.04 39 148.72 43
Laboratory costs 76.14 24 77.09 22
Support staff costs 0.02 0 0.01 0
Multidisciplinary team costs NA 0 0.41 0
District health staff costs 0.02 0 0.01 0
Drugs and commodities 119.28 37 119.28 34
Operating costs 0.38 0 0.56 0
Equipment costs 0.77 0 0.51 0
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Although the average total cost of each of the 
service areas was higher in the intervention arm 
relative to the control arm, when disaggregated into 
their respective cost components, those differences 
showed wider variation within each study arm that 
did not match the same pattern as the total average 
cost. Additional analysis of the disaggregated cost 
components showed that these variations were 
primarily a result of three key input factors. These 
are:
1. Variation in provider responses on average 
time spent per patient per service area, the 
average number of visits per patient per year 
by service area, the average time spent per 
patient per visit, and the quantity of drugs and 
commodities used for each patient per visit. The 
data collection strategy relied heavily on staff 
responses, and even though all facilities noted 
following standard treatment protocols for all 
five service areas, these treatment protocols do 
not stipulate standard time spent per patient 
per visit. Equally important, the quantity of 
certain drugs and commodities vary by patient 
need while the number of visits per patient per 
year are dependent on patient-specific factors 
(availability, accessibility, and affordability). 
2. The allocation key used in apportioning shared 
costs. The proportion of patient or patient 
visits by service area assumes that all patients 
utilize facility resources equally regardless of 
the type of service provided. In other words, a 
patient who comes for ANC services receives 
similar services as a patient who comes for FP, 
PMTCT, PNC, and pediatric ART. While not the 
most precise method for apportioning shared 
costs, this method was the most efficient given 
the study limitations. Additionally, the method 
weights MNCH patients more, particularly ANC 
patients, who represent the largest share of 
patients—9 percent of patients in the control arm 
and 10 percent of patients in the intervention 
arm.
3. Financial records on operating and equipment 
costs showed variation within each arm. 
Hospitals reported higher operating costs, and 
these costs were higher on average for facilities 
in the intervention arm relative to the control 
arm. Similarly, available records showed medical 
equipment used in the control arm were slightly 
newer (average purchase date May 2016) than 
the intervention arm (average purchase date 
February 2015). This means that on average the 
estimated value of equipment used for patients 
in the control arm was slightly higher than in the 
intervention arm. 
With these key variations in mind, the cost drivers 
are discussed by service area below. 
Antenatal care
Cost drivers for ANC services vary between 
the control and intervention arms. The largest 
contributor to costs in the control arm is laboratory 
services, accounting for 53 percent of the total 
average ANC cost, a major portion of which is 
the result of the high cost of HIV, STI, and blood 
grouping tests. The second largest share of ANC 
service costs provided under the current guidelines 
is clinical staff costs (22%) followed by equipment 
costs (14%), operating costs (7%), and drugs and 
commodities (4%). Similar to control facilities, lab 
costs account for the largest share (41%) of ANC 
services provided by IMPROVE intervention facilities. 
However, this is followed by the cost of oversight 
and support provided by the multidisciplinary team 
(20%), then clinical staff cost (18%), operating costs 
(9%), equipment costs (7%), and, lastly, the cost of 
drugs and commodities (5%). The key contributing 
factor to the difference between the study arms is 
the inclusion of costs associated with the oversight 
and support provided by the multidisciplinary team 
at each intervention facility. Of the $72 (35%) 
cost difference between intervention and control 
facilities, an estimated $55 can be attributed to the 
cost of the multidisciplinary team, representing a 
substantial two-thirds of the cost difference between 
intervention and control ANC services.  
Family planning
When disaggregated into the eight cost components, 
cost drivers for control and intervention facilities 
mostly follow similar distribution patterns. For FP 
services in the control arm, costs are split across 
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clinical staff costs and the costs of drugs and 
commodities, with clinical staff costs accounting 
for the largest share (58%) while drugs and 
commodities account for the remainder (42%). In the 
intervention arm, FP services are split across three 
cost components—clinical staff (43%), drugs and 
commodities (31%), and the multidisciplinary team 
(26%). In both arms, the allocated costs (support 
staff, operating costs, equipment costs) account for 
a minimal share in total costs, less than 1 percent. 
PMTCT
The largest share of the unit cost of PMTCT 
services is the cost of drugs and commodities, 
estimated to be 39 percent of the average cost 
of services at control facilities and 37 percent of 
the total average cost at intervention facilities, per 
woman per year. As expected, ARVs account for 
the largest share of PMTCT costs at 36 percent 
and 34 percent of the total average unit cost in 
control and intervention facilities, respectively. After 
drugs and commodities, the cost of clinical staff 
time account for approximately 30 percent and 31 
percent of total average PMTCT costs in control and 
intervention facilities, respectively. Laboratory costs 
account for the third largest share of costs (26%) of 
PMTCT services in both the control and intervention 
facilities. At this point, the cost distribution for both 
control and interventions diverge. In the control arm, 
the remainder of the share of cost of PMTCT services 
are divided into equipment (3%) and operating costs 
(2%). In the intervention arm, the remainder of the 
share of PMTCT service costs are split by operating 
(2.6%), multidisciplinary team (2%), and equipment 
(1.6%) costs. 
Postnatal care
In control facilities, clinical staff costs account for a 
little more than half (55%) of the estimated average 
unit cost of PNC, followed by equipment costs (20%), 
operating costs (16%), and the cost of drugs and 
commodities (9%). In intervention facilities, clinical 
staff costs also account for a little more than half 
(51%) of the share of the cost of PNC services, 
followed by equipment (15%) and operating costs 
(13%), with the remainder split evenly between 
the cost of drugs and commodities (11%) and the 
multidisciplinary team (11%). As with ANC cost, the 
$11 cost of the multidisciplinary team represents 
more than two-thirds of the $13 cost difference 
between PNC services in intervention facilities 
relative to control facilities. 
Pediatric ART
The cost distribution of pediatric ART services follows 
the same pattern for both control and intervention 
facilities. Clinical staff costs represent the largest 
share of pediatric ART service costs, accounting for 
39 percent of total average cost in control facilities 
and 43 percent in intervention facilities, per child 
per year. In both study arms, the cost of drugs and 
commodities account for the second largest share of 
costs, accounting for 37 percent in control facilities 
and 35 percent in intervention facilities. Laboratory 
costs account for the remainder of the share of 
total average pediatric ART services at 24 percent 
in control facilities and 22 percent in intervention 
facilities. 
DISCUSSION
The cost of the IMPROVE intervention, especially the 
integrated approach for FP, PMTCT, and pediatric 
ART, is not prohibitive and has the potential to 
improve coordination of care at relatively low cost 
to existing services. More specifically, this relatively 
low-cost difference suggests that the IMPROVE 
intervention’s integrated approach does not require 
substantial investments to provide integrated 
services for HIV-positive women and their HIV 
care. With a relatively low cost, and potential for 
overall improvement in coordinated care, it is worth 
exploring the expansion of the IMPROVE intervention 
beyond PMTCT programming, and to adapt it to 
additional health areas and care models. 
As an entry point for the intervention, the 
coordinating efforts of the multidisciplinary team 
adds some costs to ANC services relative to the 
other service areas. However, this is likely because 
ANC is often where women needing additional 
support are identified and providers likely spend 
more time in the multidisciplinary groups discussing 
individualized care plans, supplementary support, 
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and/or additional home visits The multidisciplinary 
team’s higher cost-share of ANC services relative 
to the lower cost-share of subsequent services 
(FP, PNC for HIV-negative women, PMTCT for HIV-
positive women), suggests that the early investment 
in ANC services reduces the need for additional 
care coordination in PMTCT and other MNCH 
services. In an already overburdened and resource 
strained healthcare system, reducing the need 
for this additional care management could free 
up valuable financial and human resources to be 
utilized elsewhere. The opportunity to repurpose 
these resources, coupled with the low cost of the 
intervention, suggests that the IMPROVE model can 
have multiple beneficial effects upon the overall 
healthcare system.
A key lesson from the IMPROVE intervention is 
that there is a need to explore the possibility that 
integration and coordination across other MNCH-
related programs (e.g., malaria, nutrition) at a key 
service entry point like ANC may reduce the cost 
of additional support services in the subsequent 
service areas outlined above (FP, PNC, PMTCT, and 
pediatric ART). Future studies will need a more 
comprehensive approach to track patient resource-
use (while ensuring there are ethical safeguards 
in place) to better understand and document how 
investment at key service entry points relates to 
future service utilization and, possibly, gain long-
term efficiencies in service delivery. 
LIMITATIONS
	y The study was geographically limited to Maseru 
district, which may not be representative of the 
entire country.
	y Several costs pertaining to the intervention were 
not available: pre-implementation costs for the 
development of job aids, training at the site level 
for use of these aids, and the start-up cost of the 
multidisciplinary team meetings. The incremental 
cost of the additional home visit was also not 
available, as it was performed for all patients 
(including non-study participants) and across 
all sites (including non-study facilities); as such 
it could not be allocated to either the control or 
intervention arm.
	y In most cases, clinical and support staff were only 
able to provide a best estimate of the amount of 
time spent with patients in each type of service 
rather than actual observed time. While it was 
the most efficient data collection methodology for 
the study, these estimates are likely subject to 
reporting bias. 
	y National averages had to be used as proxy for 
some cost data (e.g., government lab salaries, 
laboratory sample transportation). The number 
of PNC patients or patient visits could not be 
triangulated with DHIS2 or other sources to 
verify accuracy. This has implications for the 
methodology used to apportion costs by each 
service area’s proportion of number of patients or 
patient clinic visits and overall cost estimates. 
	y Data for one category of operating costs—external 
services—were available for only one of the control 
facilities and were estimated to be over $20,000 
in one year. The inclusion of these data would 
have skewed the average operations cost in the 
control arm, and as such they were excluded from 
the results. 
CONCLUSIONS
The IMPROVE intervention resulted in a better 
understanding of inefficiencies at the service 
delivery level in Lesotho and helped to spark 
conversations around the importance of patient-
centered care and efficient, low-cost methods of 
improving both facility- and community-based care 
models. The intervention proved to have a minimal 
additional cost and is potentially scalable beyond 
the Maseru district in Lesotho, and beyond PMTCT/
MNCH services. The collection of cost data also 
identified areas in which there is limited visibility into 
cost and operational data (see limitations above), 
which can potentially help inform the design of 
future cost studies in similar settings. Cost data from 
IMPROVE will continue to be utilized beyond this final 
analysis, and will contribute to a growing database of 
cost data via the Global Health Costing Consortium, 
helping to inform future planning methods, models, 
and analysis focused on HIV testing, PMTCT, MNCH, 
and FP. 
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